Current challenges in tobacco control

International Journal of Tuberculosis and Lung Disease

Volumn 8, Issue 10, 2004, Pages 1160-1172

  Slama, K ^a,b  

^a Tobacco Prevention Division   (France)

^b INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

Author keywords

FCTC; Nicotine; Smoking; Tobacco

Indexed keywords

AMFEBUTAMONE; MONOAMINE OXIDASE INHIBITOR; NICOTINE;

ADDICTION; AUTOMUTILATION; BONE DENSITY; CANCER SUSCEPTIBILITY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COST EFFECTIVENESS ANALYSIS; CULTURAL FACTOR; DRUG CONTRAINDICATION; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG INDICATION; ENVIRONMENT; EPIDEMIOLOGICAL DATA; FETUS DEATH; GENETIC DIFFERENCE; GENETICS; HEALTH CARE POLICY; HEALTH HAZARD; HEALTH PROGRAM; HEALTH STATUS; HIP FRACTURE; HUMAN; LAW; LUNG CANCER; MARKETING; MEDICAL SOCIETY; MORTALITY; NICOTINE REPLACEMENT THERAPY; PREVALENCE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PUBLIC HEALTH; RESPIRATORY TRACT DISEASE; REVIEW; SMOKING; SMOKING CESSATION; SOCIAL ENVIRONMENT; TOBACCO; TOBACCO INDUSTRY;

ALGORITHMS; FEMALE; FORECASTING; HUMANS; LEGISLATION; MALE; PUBLIC OPINION; SEX FACTORS; SMOKING; SMOKING CESSATION; TOBACCO INDUSTRY; TOBACCO USE DISORDER;

EID: 5644239682     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. World Health Organization. The World Health Report 2002. Reducing Risks, Promoting Healthy Life. Geneva, Switzerland: WHO, 2002.
2. Chapman S. Reducing tobacco consumption. NSW Public Health Bulletin 2003; 14: 46-48.
3. Shafey O, Dolwick S, Guindon G E, eds. Tobacco Control Country Profiles. 2nd ed. World Health Organization, International Union Against Cancer, American Cancer Society joint publication, 2003. http://www.who.int
4. Porter S, Jackson K, Trosclair A, Pederson L L. Prevalence of current cigarette smoking among adults and changes in prevalence of current and some day smoking-United States, 1996-2001. MMWR Weekly 2003; 52: 303-307. http://www.cdc. gov/mmwr/preview/mmwrhtml/mm5214a2.htm
5. Canadian Tobacco Use Monitoring Survey (CTUMS). Summary of Results for Wave 1 (February to June) of 2003. Health Canada, 2003. www.hc-sc.gc.ca/hecs- sesc/tobacco/research/ ctums/2003/summary_first.2003.html
6. Guindon G E, Boisclair D. Past, current, and future trends in tobacco use. Washington DC: World Bank, 2003. http:// www1.worldbank.org/tobacco/ publictions.asp
7. Kaufman N J, Nichter M. The marketing of tobacco to women: Global perspectives. In Samet J K, Yoon S-Y, eds. Women and the Tobacco Epidemic. Challenges for the 21st Century. WHO/ NMH/TFI/01.1 Geneva, Switzerland: WHO, 2001.
8. Gajalakshmi C K, Jha P, Ranson K, Nguyen S. Global patterns of smoking and smoking-attributable mortality. In: Jha P, Chaloupka F, eds. Tobacco Control in Developing Countries. New York, NY: Oxford University Press, 2000.
9. Global Youth Tobacco Survey. Centers for Disease Control and Prevention/World Health Organization. http://www.cdc.gov/ tobacco/global/gyts/ globaluse02.htm
10. Peto R, Lopez A D, Boreham J, Thun M, Health C Jr. Mortality from Smoking in Developed Countries 1950-2000. Oxford, UK: Oxford University Press, 1994. Updated, 1998.
11. Jha P, Chaloupka FJ. Curbing the Epidemic. Governments and the Economics of Tobacco Control. Washington, DC: The World Bank, 1999.
12. Yach D, Hawkes C, Gould C L, Hofman K J. The global burden of chronic diseases. Overcoming impediments to prevention and control. JAMA 2004; 291: 2616-2622.
13. United Nations Ad Hoc Inter-Agency Task Force on Tobacco Control. Report of the Secretary-General. 2004. E/2004/55. www.un.org/esa/coordination/ecosoc/ document.htm
14. Doll R. Conversation with Sir Richard Doll. Br J Addict 1991; 86: 365-377.
15. Wynder E L. Tobacco as a cause of lung cancer: some reflections. Am J Epidemiol 1997; 146: 687-694.
16. Wilkinson L. Sir Austin Bradford Hill: medical statistics and the quantitative approach to prevention of disease. Addiction 1997; 92: 657-666.
17. US Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004. www.cdc.gov/tobacco/sgr/ sgr_2004/index.htm
18. US Department of Health and Human Services. Reducing Tobacco Use: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2000.
19. British Medical Association Board of Science and Education & Tobacco Control Resource Centre. Smoking and Reproductive Life. The impact of smoking on sexual, reproductive and child health. London, UK: BMA. 2004. www.bma.org.uk
20. Hill S E, Blakely T A, Kawachi I, Woodward A. Mortality among 'never smokers' living with smokers: two cohort studies, 1981-4 and 1996-9. BMJ 2004; 328: 988-989.
21. Ostbye T, Taylor D H. The effect of smoking on years of healthy life (YHL) lost among middle-aged and older Americans. Health Serv Res 2004; 39: 531-552.
22. Pickles T, Liu M, Berthelet E, Kim-Sing C, Kwan W, Tyldesley S. The effect of smoking on outcome following external radiation for localized prostate cancer. J Urology 2004; 171: 1543-1546.
23. Moller A M, Villebro N, Pederson T, Tonnesen H. Effect of preoperative smoking intervention on postoperative complications: a randomised clinical trial. The Lancet 2002; 359: 114-117.
24. Wyser C, Bolliger CT. Smoking-related disorders. In: Bolliger CT, Fagerström KO, eds. The Tobacco Epidemic. Basel: Karger. 1997.
25. US Department of Health and Human Services. The Health Consequences of Smoking: Cardiovascular Disease. A Report of the Surgeon General. DHHS Publication No. (PHS)84-50204. Rockville, MD: US Department of Health and Human Services, Public Health Service, Office on Smoking and Health, 1983.
26. Weinstein N D, Slovic P, Waters E, Gibson G. Public understanding of the illnesses caused by cigarette smoking. Nicotine Tob Res 2004; 6: 349-355.
27. Grémy I, Halfen S, Sasco A, Slama K. Les Connaissances, Attitudes et Perceptions des Franciliens à l'égard du Tabac. Paris: ORS de l'Ile de France, 2002: pp 275.
28. Chapple A, Ziebland S, McPherson A. Stigma, shame, and blame experienced by patients with lung cancer: qualitative study. BMJ 2004; 328: 1470.
29. Doward J. Tobacco giant funds 'bad gene' hunt. The Observer, 30 May 2004.
30. Cookson W. The Gene Hunters. Adventures in the Genome Jungle. London, UK: Aurum Press, 1994.
31. Wells A J. An estimate of adult mortality in the United States from passive smoking. Environ Int 1988; 14: 249-265.
32. Slama K. Active smoking. Eur Resp Mon 2000; 15: 305-321.
33. Mackay J, Eriksen M. The Tobacco Atlas. Geneva, Switzerland: World Health Organization, 2002.
34. Bozecevic I, Gilmore A B, Novotny T E. Tobacco use, a major public health issue in South East Europe. Eurohealth 2003-2004; 9: 1-4.
35. World Health Organization Regional Office for the Eastern Mediterranean. The cigarette 'transit' road to the Islamic Republic of Iran and Iraq. Illicit tobacco trade in the Middle East. WHO-EM/TFI/011/E/G Cairo, Egypt: WHO EMRO, 2003.
36. Yach D, Bettcher D. Globalisation of tobacco industry influence and new global responses. Tob Control 2000; 9: 206-216.
37. Slama K. Tobacco Control and Prevention. A Guide for Low Income Countries. Paris, France: International Union Against Tuberculosis and Lung Disease, 1998.
38. Aghi M, Asma S, Yeong C C, Vainathan R. Initiation and maintenance of tobacco use. In: Samet JM, Yoon S-Y, eds. Women and the Tobacco Epidemic. Challenges for the 21st Century. Canada: World Health Organization, 2001.
39. Hill C, Laplanche A. Le tabac en France les vrais chiffres. Paris: La Documentation Française. 2004.
40. Woollery T, Trosclair A, Husten C, Caraballo R C, Kahende J. Cigarette smoking among adults-United States, 2001. MMWR 2003; 52: 953-956.
41. DiFranza J R, Savageau J A, Rigotti N A, et al. Development of symptoms of tobacco dependence in youths: 30 month follow-up data from the DANDY study. Tob Control 2002; 11: 228-235.
42. Hensrudd D D, Sprafka J M. The smoking habits of Minnesota physicians. Am J Public Health 1993; 83: 415-417.
43. World Health Organization. Tobacco or Health: A Global Status Report. Geneva, Switzerland: WHO, 1997.
44. Currie C, Hurrelmann K, Settertobulte W, Smith R & Todd J, eds. Health and health behaviour among young people. WHO Policy Series: Health policy for children and adolescents Issue 1. Copenhagen, Denmark: WHO Regional Office for Europe, 2000.
45. National Cancer Institute. Report of the Lung Cancer Progress Review Group. Bethesda, MD: NCI, August 2001.
46. Kenkel D, Chen L. Consumer information and tobacco use. In: Jha P, Chaloupka F, eds. Tobacco Control in Developing Countries. Oxford, UK: Oxford University Press, 2000. pp: 177-214.
47. World Health Organization. Tobacco and Poverty. A vicious circle. Geneva, Switzerland: WHO, 2004.
48. Cavelaars A E J M, Kunst A E, Geurts J J M, et al. Educational differences in smoking: international comparison. BMJ 2000; 320: 1102-1107.
49. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004; 328: 1519.
50. Slama K. Evidence-based cancer prevention strategies: Tobacco control. In: Sancho-Garnier H, Anderson A, Biedermann A, Lynde E, Slama K, eds. Evidence-based Cancer Prevention: Strategies for NGOs. Geneva, Switzerland: International Union Against Cancer, 2004.
51. Efroymson D, Must E, Tanudyaya F. A Burning Issue: Tobacco Control and Development. Path Canada Guide. Ottawa, Canada, Path Canada, 2001.
52. White V M, Hopper J L, Wearing A J, Hill D J. The role of genes in tobacco smoking during adolescence and young adulthood: a multivariate behaviour genetic investigation. Addiction 2003; 98: 1087-1100.
53. Johnson E O, Chase G A, Breslau N. Persistence of cigarette smoking: familial liability and the role of nicotine dependence. Addiction 2002; 97: 1063-1070.
54. Mental Health Global Action Programme (mhGAP) of the Department of Mental Health and Substance Abuse, World Health Organization. The Neuroscience of Psychoactive Substance Use and Dependence. Geneva, Switzerland: WHO, 2004.
55. Perkins K A, Donny E, Caggiula A R. Sex differences in nicotine effects and self-administration: review of human and animal evidence. Nicotine Tob Res 1999; 1: 301-315.
56. Gritz E R, Nielsen I R, Brooks L A. Smoking cessation and gender: the influence of physiological, psychological and behavioral factors. JAMWA 1996; 51: 35-42.
57. Haselbach C, Libert O. Final Report on Project Hippo, Battelle Memorial Institute for BAT, 1963. Cited in Action on Smoking and Health UK. Tobacco Explained. The truth about the tobacco industry in its own words. ASH UK, 1998.
58. Benowitz N IL. Summary: risks and benefits of nicotine. In: Benowitz N L, ed. Nicotine Safety and Toxicity. New York, NY: Oxford University Press, 1998.
59. Balfour D, Benowitz N, Fagerström K, Kunze M, Keil U. Diagnosis and treatment of nicotine dependence with emphasis on nicotine replacement therapy. Eur Heart J 2000; 21: 438-445.
60. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders. 4th ed. Washington, DC: APA, 1994.
61. Tiffany S T, Conklin C A, Shiffman S, Clayton R R. What can dependence theories tell us about assessing the emergence of tobacco dependence? Addiction 2004; 99 (Suppl 1): 78-86.
62. Hammersly R, Reid M. Why the pervasive addiction myth is still believed. Addict Res Theory 2002; 10: 7-30.
63. Slama K. Is nicotine addiction an answer or a question? Int J Tuberc Lung Dis 2003; 7: 809-810.
64. Nutbeam D. Health promotion effectiveness-The questions to be answered. In International Union for Health Promotion and Education. The Evidence of Health Promotion Effectiveness. 2nd ed. ECSC-EC-EAEC. Paris, France: IUHPE, 2000.
65. Chapman S. Advocacy in public health: roles and challenges. Int J Epidemiol 2001; 30: 1226-1232.
66. Sargent J D, Beach M L, Dalton M A, et al. Effect of seeing tobacco use in films on trying smoking among adolescents: cross sectional study. BMJ 2001; 323: 1394-1397. (see also: Sargent J D, DiFranza J R. Tobacco control for clinicians who treat adolescents. CA Cancer J Clin 2003; 53: 102-123. http:// CAonline.AmCancerSoc.org)
67. Sargent J D, Beach M L, Dalton M A, et al. Effect of seeing tobacco use in films on trying smoking among adolescents: cross sectional study. BMJ 2001; 323: 1394-1397. (see also: Sargent J D, DiFranza J R. Tobacco control for clinicians who treat adolescents. CA Cancer J Clin 2003; 53: 102-123. http:// CAonline.AmCancerSoc.org)
68. Dunn W L. Phillip Morris Internal Memo. 1972. Bates N° 2024273959/3975; http://tobaccodocuments.org/landman/ 2024273959-3975.html PDF Version: http://legacy.library. ucsf.edu/cgi/getdoc?tid=txy74e00&fmt= pdf&ref=results
69. Green S J. Transcript of a note by S. J. Green, 1 January 1980, cited in Hammond R, Rowell A, eds. Trust Us. We're the Tobacco Industry. 2001. Published by Campaign for Tobacco-Free Kids (US)/Action on Smoking and Health UK.
70. Philip Morris Internal Document. 1992. Bates N° 2024705949/ 5981; http://tobaccodocuments.org/landman/2024705949-5981. html PDF Version: http://ligacy.library.ucsf.edu/cgi/getdoc?tid= aak98e00&fmt=pdf&ref= results
71. Lawlor D A, Frankel S, Shaw M, Ebrahim S, Davey Smith G. Smoking and ill health: does lay epidemiology explain the failure of smoking cessation programs among deprived populations? Am J Public Health 2003; 93: 266-270.
72. Warner K E, Jacobsen P D, Kaufman N J. Innovative approaches to youth tobacco control: introduction and overview. Tob Control 2003; 12 (Suppl 1): i1-i5.
73. Farrelly M C, Niederdeppe J, Yarsevich J. Youth tobacco prevention mass media campaigns: past, present, and future directions. Tob Control 2003; 12 (Suppl 1): i35-i47.
74. Lantz P M, Jacobson P D, Warner K E, et al. Investing in Youth tobacco control: a review of smoking prevention and control strategies. Tob Control 2000; 9: 47-63.
75. Chen X, Li G, Unger J B, Liu X, Johnson C A. Secular trends in adolescent never smoking from 1990-1999 in California: an age-period-cohort analysis. Am J Public Health 2003; 93: 2099-2104.
76. Centers for Disease Control and Prevention. Best Practices for Comprehensive Tobacco Control Programs-August 1999. Atlanta GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 1999. Reprinted, with corrections.
77. Fichtenberg C M, Glantz S A. Effect of smoke-free workplaces on smoking behaviour: systematic review. BMJ 2002; 325: 188-191. See also the accompanying editorial, West R. Banning smoking in the workplace. BMJ 2002; 325: 174-175.
78. Fichtenberg C M, Glantz S A. Effect of smoke-free workplaces on smoking behaviour: systematic review. BMJ 2002; 325: 188-191. See also the accompanying editorial, West R. Banning smoking in the workplace. BMJ 2002; 325: 174-175.
79. Lando H A, Gritz E R. Smoking cessation techniques. JAMWA 1996; 51: 31-34.
80. Slama K, Karsenty S, Hirsch A. The effectiveness of minimal intervention by general practitioners with their smoking patients: a randomised, controlled trial in France. Tob Control 1995; 4: 162-169.
81. Fiore M C, Bailey W C, Cohen S J, et al. Treating Tobacco Use and Dependence. Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services, Public Health Service, 2000.
82. Epps R P, Manley M W, Grande D, Lynch B S. How clinicians can affect patient smoking behaviour through community involvement and clinical practice. JAMWA 1996; 51: 43-47.
83. Willemsen M C, Wagena E J, van Schayck C P. [The efficacy of smoking cessation methods available in the Netherlands: a systematic review based on Cochrane data] [Article in Dutch] Ned Tijdschr Geneeskd 2003; 147: 922-927. [Abstract in English].
84. Lancaster T, Stead L, Silagy C, Sowden A. Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. BMJ 2000; 321: 355-358.
85. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation (Cochrane Review). In: The Cochrane Library, Issue 2. Chichester, UK: John Wiley & Sons Ltd, 2004.
86. Martinez-Raga J, Keaney F, Sutherland G, Perez-Galvez B, Strang J. Treatment of nicotine dependence with bupropion SR: review of its efficacy, safety and pharmacological profile. Addict Biol 2003; 8: 13-21.
87. Health Canada Online Advisory. Health Canada advises Canadians of stronger warning for SSRIs and other newer anti-depressants. www.hc-sc.gc.ca/english/protection/warnings/ 2004/2004_31.htm
88. Novotny T, Cohen JC, Yurekli A, Sweanor D, de Beyer J. Smoking cessation and nicotine-replacement therapies. In: Jha P, Chaloupka F, eds. Tobacco Control in Developing Countries. New York, NY: Oxford University Press, 2000.
89. Pierce J P, Gilpin E A. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA 2002; 288: 1260-1264.
90. Shibuya K, Ciecierski C, Guindon E, Bettcher D W, Evans D B, Murray C J. WHO Framework Convention on Tobacco Control: development of an evidence based global public health treaty. BMJ 2003; 327: 154-157.
91. McNeill A, Foulds J, Bates C. Regulation of nicotine replacement therapies (NRT): a critique of current practice. Addiction 2001; 96: 1757-1768.
92. Royal College of Physicians. Nicotine Addiction in Britain. London, UK: Royal College of Physicians, 2000.
93. Henningfield J E, Moochan E T, Zeller M. Regulatory strategies to reduce tobacco addiction in youth. Tob Control 2003; 12 (Suppl 1): i14-i24.
94. Hughes J R, Hecht S S, Carmella S G, Murphy S E, Callas P. Smoking behaviour and toxin exposure during six weeks use of a potential reduced exposure product: Omni. Tob Control 2004; 13: 175-179.
95. Pierce J P. Harm reduction or harm maintenance? Nicotine Tob Res 2002; 4: S53-S54.
96. Hatsukami D K, Slade J, Benowitz N L, et al. Reducing tobacco harm: research challenges and issues. Nicotine Tob Res 2002; 4: S89-S101.
97. Gilljam H. Galanti M R. Role of snus (oral moist snuff) in smoking cessation and smoking reduction in Sweden. Addiction 2003; 98: 1183-1189.
98. Kozlowski L T. Harm reduction, public health, and human rights: smokers have a right to be informed of significant harm reduction options. Nicotine Tob Res 2002; 4: S55-S60.
99. Bolinder G. Long-term use of smokeless tobacco. Cardiovascular mortality and risk factors. Stockholm, Sweden: Karolinska Institute, 1997.
100. Ayo-Yusuf O A, Swart T J P, Pickworth W B. Nicotine delivery capabilities of smokeless tobacco products and implications for control of tobacco dependence in South Africa. Tob Control 2004; 13: 186-189.
101. Rose G. Sick individuals and sick populations. Int J Epidemiol 1985; 14: 32-38, reprinted 2001; 30: 427-432.
102. Rose G. Sick individuals and sick populations. Int J Epidemiol 1985; 14: 32-38, reprinted 2001; 30: 427-432.
103. Martin E G, Warner K E, Lantz P M. Tobacco harm reduction: what do the experts think? Tob Control 2004; 13: 123-128.